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Introduction: SLIT2, a secreted protein, has been found to inac-
tivate Cdc42 GTPase to modulate neural cell migration. However, 
alteration of SLIT2-mediated Cdc42 in terms of migration regulation 
remains undefined in esophageal squamous cell carcinoma (ESCC).
Methods: We report here in ESCC cell, animal, and clinical models 
that SLIT2 acts as a migration suppressor and serves as a prognostic 
biomarker.
Results: The immunohistochemistry data indicated that 31.8% 
(49 of 154) of tumors from ESCC patients showed low expres-
sion of SLIT2 protein which correlated with poor overall survival 
and disease-free survival. DNA methylation analysis suggested 
that promoter hypermethylation is responsible for low expres-
sion of SLIT2 in ESCC. Knockdown of SLIT2 increased ESCC 
cell migration, while SLIT2 stable overexpression reduced cell 
migration. ESCC cells treated with conditioned media from cells 
overexpressing SLIT2 also suppressed cell migration. Importantly, 
silencing of SLIT2 decreased the complex formation, and thus 
induced Cdc42 activity and promoted membrane localization of 
focal adhesion kinase and Paxillin. Anti-metastatic effect of SLIT2 
was confirmed in an experimental metastasis model of SLIT2 
knockdown ESCC cells.
Conclusion: Our results provide novel evidence that low expression 
of SLIT2 correlates with poor prognosis and promotes metastasis in 
ESCC, which may be regulated by the Cdc42-mediated pathways.
Key Words: SLIT2, Cdc42, Focal adhesion kinase, Esophageal 
squamous cell  carcinoma, Prognosis.
(J Thorac Oncol. 2015;10: 189–198)
Over the past decade, esophageal cancer has become the most common cancer in some areas of the world and 
affects more men than women.1 There are two predominant 
subtypes of esophageal cancer, esophageal squamous cell car-
cinoma (ESCC) and esophageal adenocarcinoma. The incidence 
of ESCC is higher than that of esophageal adenocarcinoma, 
especially in East Asian countries. ESCC forms in squamous 
cells and most often occurs in the upper and middle part of the 
esophagus. Tobacco smoking, alcohol intake, and diet are impor-
tant risk factors for ESCC.2,3 Despite improvement in clinical 
diagnostic tools and therapeutic approaches to ESCC, the prog-
nosis of ESCC is extremely poor because of high rate of cancer 
recurrence due to early regional and lymph nodes metastasis.1,4 
Metastasis is a multistep process that includes mobilization of 
tumor cells into lymphatic and blood vessels, extravasation, 
invasion of target sites, and growth in distant organs.5 Therefore, 
an understanding of the metastasis-related genes and pathways 
is urgently needed for the development of effective therapeutic 
modalities and diagnostic approaches for ESCC.
Alterations of metastasis-related genes and signal-
ing have been reported in ESCC.6 For example, Rho family 
GTPase 3, RND3 (also called RhoE) is downregulated in 
ESCC tissues and cell lines. The downregulation of RhoE 
expression promotes cell invasion and significantly decreases 
phosphatase and tensin homolog (PTEN) protein expression 
and increases p-AKT level.7 In addition, migfilin, a protein 
component of focal adhesions, downregulates ESCC motil-
ity through promoting GSK3β-mediated degradation of 
β-catenin.8 Although some metastasis-related genes have 
been identified in ESCC, they still cannot explain clearly the 
mechanisms of metastasis in ESCC.
Molecular mechanism of SLIT2 in the regulation of neu-
ron cell migration has been proposed: Secretory glycoprotein 
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SLIT2 interacts with its membrane receptor ROBO1 leading 
to the activation of SLIT-ROBO Rho GTPase activating pro-
tein 1 (srGAP1). The srGAP1 transduces the SLIT2 signal in 
neuronal migration by inactivating the GTPase Cdc42.9,10 The 
reduction of active Cdc42 eventually decreases actin polymer-
ization.11,12 Therefore, activation of SLIT2–ROBO1–srGAP1 
signaling pathway tends to result in the suppression of neu-
ron cell migration. Cell migration is important in various 
biological processes ranging from embryonic development 
to metastasis. Recently, we found that knockdown of the 
SLIT2 increases cell migration in lung cancer.13 Therefore, 
we hypothesized that the alteration of SLIT2-mediated Cdc42 
signaling pathway may also occur in human aerodigestive 
tract cancer, such as esophageal cancer.
To investigate the detailed clinical and biological signifi-
cance of SLIT2-mediated metastasis suppression effect in ESCC, 
we performed comprehensive analyses in clinical, cell, and xeno-
graft models, and discovered SLIT2 as a potential molecular tar-
get for anti-cancer therapeutic modulation in human ESCC.
MATERIALS AND METHODS
Clinical Samples of ESCC Patients
Paired resected tumor and normal esophageal tissues 
were obtained from 154 ESCC patients who underwent cura-
tive surgeries at the National Cheng-Kung University Hospital 
between 1991 and 2008 with informed consent from all the 
patients and approval of institutional review board. The 
patients with clinicopathological characteristics are shown 
in Supplemental Digital Content 1 (http://links.lww.com/
JTO/A715). Two patients who died of post-operative mortal-
ity were removed from the survival analysis. Overall survival 
was calculated from the day of surgery to the date of death 
or the last follow-up for 152 ESCC patients (dead patients: 
145, censored patients: 7). The mean follow-up period was 
25 months (range, 1–209 months). For the mRNA and DNA 
methylation assays, 50 samples showing greater than 70% 
tumor tissue when observed within each of the resected tis-
sue sections at low-power (×100) magnification under a light 
microscope were selected. Genomic DNA from frozen pri-
mary tumor tissues was prepared using proteinase K digestion 
and phenol–chloroform extraction. For RNA expression assay, 
total RNA was prepared from paired tumor and frozen nor-
mal tissues using Trizol reagent (Invitrogen, Carlsbad, CA). 
cDNA was synthesized using SuperScript reverse transcrip-
tase (Invitrogen) according to the manufacturer’s instructions.
Immunohistochemical Analysis
Paraffin blocks of tumors were sectioned into 5 μm 
slices and then processed using standard deparaffinization 
and rehydration techniques. Antibodies used and their experi-
mental conditions are summarized in Supplemental Digital 
Content 2 (http://links.lww.com/JTO/A716). Staining “inten-
sity” measurements were translated into the four-tier system 
as strong (3+), moderate (2+), weak (1+), or negative (−) stain-
ing, which were judged by the comparison of stained intensity 
between tumor and surrounding normal tissues. Staining “per-
centage” was scored 4, 3, 2, or 1 if greater than 75%, 50% to 
75%, 25% to 50%, or less than 25% area were stained, respec-
tively, of tumor cell cytoplasm, membrane or cell junction. 
Five randomly selected high-power fields in adjacent noncan-
cerous tissue were included as negative control samples and 
10 randomly selected high-power fields in tumor tissue were 
used for scoring. As a result, the staining was graded as “low 
expression” if cytoplasm staining intensity multiplied by per-
centage was less than or equal to 4.
Quantitative Reverse-Transcriptase Polymerase 
Chain Reaction and Quantitative Methylation-
Specific Polymerase Chain Reaction Assays
Expression level of SLIT2 mRNA was assayed by 
quantitative reverse-transcriptase polymerase chain reaction 
(RT-qPCR) analysis using β-actin gene as internal control. 
Relative quantitation using the comparative Ct method to 
analyze data acquired with ABI 7900 HT sequence detection 
systems and StepOnePlus Real-Time PCR system (Applied 
Biosystems, Carlsbad, CA) was performed according to the 
manufacturer’s protocol. The mRNA level of SLIT2 was calcu-
lated using 2−ΔCt (ΔC
t
 = C
t-SLIT2
 − C
t-β-actin). Low SLIT2 expression 
was defined as the mRNA expression in tumor tissue divided 
by the mRNA expression in paired normal tissue less than 0.5. 
To measure the DNA methylation level, positive control sam-
ples with unmethylated DNA and CpG Methylase (M. SssI) 
methyltransferase-treated methylated DNA were included for 
each set of PCR. Relative quantitation using the comparative 
Ct method to analyze data acquired with StepOnePlus Real-
Time PCR system (Applied Biosystems). The internal control 
of quantitative methylation-specific PCR (qMSP) is the value 
of β-actin. The hypermethylation of SLIT2 gene was defined 
as the amplification of more M (methylated) products than 
U (unmethylated) products from the tumor sample. Primers 
for RT-qPCR and qMSP analyses are listed in Supplemental 
Digital Content 3 (http://links.lww.com/JTO/A717).
Cell Lines, Knockdown or Ectopically Expressed 
SLIT2 Analysis, and 5-aza-2′-deoxycytidine 
(5-aza-dC) Treatment of ESCC Cells
Taiwanese ESCC cell lines CE48T and CE81T were pur-
chased from the Bioresource Collection and Research Center 
(Hsinchu, Taiwan) and SV40 immortalized human esopha-
geal squamous cell line HET-1A14 was purchased from the 
American Type Culture Collection (Manassas, VA), where they 
were characterized by DNA-fingerprinting and isozyme detec-
tion. The HET-1A cell line was cultured in BEBM (Bronchial/
Tracheal Epithelial Cell Basal Medium; CELL Applications, 
San Diego, CA), and CE48T and CE81T cells were maintained 
in Dulbecco's Modified Eagle's medium (Invitrogen). Media 
were supplemented with 10% fetal bovine serum (Invitrogen) 
and 1% penicillin/streptomycin (Invitrogen). Full length SLIT2 
cDNA (4950 bp) was PCR amplified and subcloned into the 
pcDNA3.1 expression vector.13 Interference RNA (siRNA) 
sequence of SLIT2 are shown in Supplemental Digital Content 
3 (http://links.lww.com/JTO/A717). The cells were treated 
with 50 μM 5-aza-dC (Sigma, MO) for three doubling times 
because as DNA replication progresses, the 5-aza-dC nucleo-
side inhibitor that is incorporated into the DNA will induce 
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DNA demethylation. The cells were then harvested for MSP, 
RT-PCR, Western blot, and migration assays.
Western Blotting, Immunofluorescence 
Staining, and Confocal Microscopic Analysis
Cells were lysed and lysates were centrifuged at 
13,000 rpm for 10 minutes at 4°C, sodium dodecyl sulfate gel 
loading buffer was added and samples containing 50 μg of 
protein were separated on 8% sodium dodecyl sulfate–PAGE 
then electro-blotted onto Immobilon-P membranes (Millipore 
Co., Bedford, MA) in transfer buffer. Cells were seeded at 
5 × 104 cells per well in six-well plates and incubated over-
night prior to immunofluorescence staining and confocal 
microscopy to keep cells ~30% confluency when the local-
ization of phosphorylated focal adhesion kinase (p-FAK) and 
p-Paxillin was analyzed. Antibodies used for immunoblotting 
and fluorescent secondary antibody are listed in Supplemental 
Digital Content 2 (http://links.lww.com/JTO/A716).
Wound Healing Assay
Wound healing assay using Culture-insert (Ibidi, 
Martinsried, Germany) was performed for CE48T and CE81T 
cells pretreated with expression plasmid or siRNA of SLIT2. 
A cell-free gap of 500 μm was created after removing the cul-
ture-insert. Cell-free gap area was determined using ImageJ 
software. The width of the open wounds was measured.
Conditioned Medium Assay
CE48T-SLIT2 cells and CE48T-EV cells (2 × 106) 
were seeded in 10 cm dish. When cells attached, the growth 
medium was replaced with serum-free medium. After 24 
hours, the conditioned medium (CM) were collected and 
incubated with the parental CE48T cells. Relative migration 
ability of CM-treated cells was measured after 24 hours.
Cdc42 Activation Assay
The Cdc42 activation assay was performed using the 
Cdc42 Activation Assay Kit (Millipore) according to the man-
ufacture’s instruction.
Antitumor Metastasis Study in Animal Model
Male severe combined immune-deficient (SCID) mice, 
5 weeks of age, were obtained from National Cheng Kung 
University Laboratory Animal Center after obtaining appropri-
ate institutional review board permission, and raised in a patho-
gen-free environment. SLIT2 knockdown CE81T cells were 
harvested after 48 hours post-transfection. Cells were then tryp-
sinized and recovered for 2 hours in media containing 20% fetal 
bovine serum. Cells (5 × 105 cells/200 μl serum-free medium) 
were intravenously injected into the tail-vein of SCID mice. Mice 
were killed after 18 weeks and lung tissues were resected, fixed 
with 10% formaldehyde, and embedded in paraffin for histologic 
hematoxylin and eosin and immunohistochemistry staining.
Statistical Analysis
Pearson’s χ2 test was used to compare the frequency 
of protein alteration in ESCC patients with different clinical 
parameters. Overall survival (OS) and disease-free survival 
(DFS) curves were calculated with the Kaplan–Meier method 
and the comparison was made using the log-rank test. mRNA 
and DNA hypermethylation correlation was performed 
using linear regression in Statistical Package for the Social 
Sciences version 17.0 (IBM, Chicago, IL). Three independent 
experiments for cell studies were analyzed unless indicated 
otherwise. Student’s t-test was used to identify significant 
differences between experimental groups in cell and animal 
studies. p value of less than 0.05 was considered statistically 
significant.
RESULTS
Correlation of Low SLIT2 Protein Expression 
with Poor Prognosis in ESCC Patients
Immunohistochemistry analysis of SLIT2 was per-
formed on samples from 154 ESCC patients (Fig. 1A). The 
data indicated that 31.8% (49 of 154) of patients showed an 
absence or low expression of SLIT2 protein. Univariate Cox 
regression analysis revealed that patients with low expression 
of SLIT2 protein had poor outcome, with a relative risk of 
death of 1.88 (p = 0.001) (Table 1). Notably, multivariate Cox 
regression analysis showed that low expression of SLIT2 pro-
tein correlated with a relative risk of death of 1.55 (p = 0.036), 
even after adjusting for gender, tumor stage, primary tumor 
invaded status, lymph node metastasis, and local/advanced 
status (Table 1).
To further define the prognostic effects of low SLIT2 
expression in 154 ESCC patients, survival curves were generated 
using the Kaplan–Meier method. Lower level of SLIT2 expres-
sion showed significantly worse prognosis in OS and DFS of 
ESCC patients (p < 0.001 and p = 0.004, respectively; Fig. 1B). 
Notably, low expression of SLIT2 protein was associated with 
poor survival in patients with locally advanced or tumor stage III 
diseases (p = 0.012 and p = 0.049, respectively; Fig. 1C).
Correlation between DNA Methylation, 
mRNA, and Protein Expression 
of SLIT2 in ESCC Patients
To verify whether promoter hypermethylation was 
involved in low SLIT2 protein expression, we carried out mRNA 
expression and DNA methylation assays of the SLIT2 gene in 
the 50 ESCC patients whose surgically resected ESCC tumors 
and the matched control samples were available. Methylation-
specific PCR assay indicated that promoter hypermethylation 
of SLIT2 gene was found in 28% of ESCC patients defined as 
the amplification of more methylated products than unmethyl-
ated products from the tumor sample (upper panel, Fig. 2A). 
The decreased SLIT2 transcripts were found in 36% of ESCC 
defined as less than 0.5 of tumor/normal by RT-qPCR assay 
(lower panel, Fig. 2A). We analyzed the correlation among 
mRNA and DNA methylation by linear regression and found 
an inverse correlation between SLIT2 DNA methylation and 
SLIT2 mRNA expression in ESCC patients (p = 0.049; Fig. 2B). 
We then correlated mRNA expression, protein expression, and 
DNA methylation using Pearson’s χ2 test. Low protein expres-
sion was significantly associated with low mRNA expression 
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(p = 0.024; left columns, Fig. 2C) and promoter hypermethyl-
ation (p = 0.040; right columns, Fig. 2C).
SLIT2 Is Reactivated by 5-aza-dC Treatment
To determine whether SLIT2 promoter methylation 
was the predominant mechanism causing loss of SLIT2 
expression, the ESCC cells, CE48T, and CE81T which showed 
low SLIT2 expression and hypermethylated SLIT2 promoter in 
comparison with the HET1-A esophageal squamous cell line 
(Supplemental Digital Content 4, http://links.lww.com/JTO/
A718), were treated with the DNA demethylating agent 5-aza-
dC. As shown in Figure 2D and E, treatment with 5-aza-dC 
successfully demethylated the promoter region of SLIT2 gene 
and restored SLIT2 mRNA expression in CE48T and CE81T 
cells. Together, the clinical correlation data and cell model 
results suggested that SLIT2 mRNA expression was down-
regulated through DNA hypermethylation.
Knockdown or Ectopically Expressed SLIT2 
Influences the Migration of ESCC Cells
Since SLIT2 low expression correlated with ESCC 
patients with advanced disease and poor prognosis, we 
hypothesized that SLIT2 may act as a migration suppressor in 
ESCC. In the ESCC cell lines, CE48T cells showed relatively 
low expression of SLIT2 (1.1% of HET1-A cells) and CE81T 
cells showed relatively high expression of SLIT2 (23.2% of 
HET1-A cells, Supplemental Digital Content 4, http://links.
lww.com/JTO/A718). Therefore, the CE48T was used as an 
ectopic SLIT2 expression model, while CE81T was used as 
a knockdown model to study SLIT2-mediated migration sup-
pression. To verify the role of SLIT2 in esophageal cancer 
migration, cells stably transfected with SLIT2 gene (CE48T/
SLIT2) or the control vector (CE48T/control) were estab-
lished. In addition, we used siRNA technology to knockdown 
SLIT2 gene in the ESCC cell line CE81T (CE81T/si-SLIT2). 
To confirm that the migration effects were studied unambigu-
ously without affecting cell growth, we conducted cell pro-
liferation and foci formation assays in SLIT2 knockdown 
CE81T and SLIT2 overexpression CE48T cells in comparison 
with their control cells. The results showed that SLIT2 knock-
down CE81T and SLIT2 overexpression CE48T did not alter 
cell proliferation and foci formation (Supplemental Digital 
Content 5, http://links.lww.com/JTO/A719). Stably express-
ing SLIT2 in CE48T cells resulted in a significant decrease in 
migration capacity as compared with the empty vector control 
cells, as determined by wound healing and transwell migra-
tion (p < 0.001; Fig. 3A and Supplemental Digital Content 
6A, http://links.lww.com/JTO/A720). To further validate the 
function of SLIT2 in ESCC cell migration and to confirm 
the specificity of our SLIT2 expression vector and si-RNA, 
reconstitution experiments by knocking down of ectopically 
expressed SLIT2 in CE48T cells (SLIT2-over/si-SLIT2) indi-
cated that SLIT2 knockdown led to increased cell migration 
(Supplemental Digital Content 6B, http://links.lww.com/JTO/
A720). Importantly, SLIT2 knockdown CE81T cells showed 
significantly greater migration capacity compared with 
untreated cells (p < 0.001; Fig. 3B), confirming the recipro-
cal relationship between SLIT2 expression and cell motility 
in esophageal cancer.
Given that SLIT2 is a secreted glycoprotein, we thus 
tested whether CM collected from SLIT2 expressing cell 
could exert anti-migration effect. To verify this, we first 
treated CE48T cells and CE81T cells with CM from either 
cells expressing SLIT2 (CE48T/SLIT2) or the control 
FIGURE 1.  Low SLIT2 protein expression correlates with poor 
survival in ESCC patients. A, Immunohistochemical analysis 
of three representative patients. SLIT2 normal expression was 
found in patient 1. Patients 2 and 3 showed low SLIT2. A 4× 
enlarged image of normal region is shown in the right panel 
of each patient, whereas an enlarged image of tumor region 
is shown in the left panel. Their original region is indicated by 
the dotted line in the middle panel (Original magnification: 
100×). The staining was graded as “normal” or “low” expres-
sion as described in the Methods. B, Patients with low SLIT2 
protein expression (−) or normal expression (+) show signifi-
cant difference in overall survival and in disease-free survival. C, 
The overall survival curves with respect to low protein expres-
sion of SLIT2 in patients with locally advanced or tumor stage 
III. ESCC, esophageal squamous cell carcinoma SLIT2.
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vector (CE48T/control), then performed migration assays. 
Importantly, inhibition of migration was observed by treat-
ment of CE48T cells and CE81T cells with CM collected from 
cells overexpressing SLIT2 (CM-SLIT2) but not cells with 
low SLIT2 expression (CM-control) (Fig. 3C). Notably, the 
concentrations of SLIT2 measured in CM were entirely con-
sistent with the scenario that secreted SLIT2 inhibits ESCC 
cell migration (upper panel, Fig. 3C). Together, these results 
indicated that SLIT2 inhibits ESCC cell migration and SLIT2 
may function in autocrine and paracrine manners.
SrGAP1-Cdc42 Signaling Is Involved in SLIT2-
Mediated Migration Suppression in ESCC
Activated SLIT2–srGAP1 signaling pathway suppresses 
neuronal cell migration by reducing active Cdc42. In addition, 
it has been reported that Cdc42 regulates cancer cell migration 
and invasion.12 To test whether srGAP1–Cdc42 signaling may 
also be involved in SLIT2-mediated migration suppression in 
ESCC, we detected the level of active Cdc42 (GTP-Cdc42) 
in CE48T with ectopically expressed SLIT2 and in CE81T 
with knockdown of SLIT2. CE48T stably expressing SLIT2 
decreased GTP-Cdc42 level (left panel, Fig. 4A), whereas 
CE81T with SLIT2 knockdown increased GTP-Cdc42 level 
(right panel, Fig. 4A).
To examine the role of srGAP1 and Cdc42 protein com-
plex formation in SLIT2-mediated migration suppression, 
CE48T and CE81T with ectopically or knockdown expressed 
SLIT2 were immunoprecipitated with srGAP1 antibody, and 
then Western blotted for srGAP1 and Cdc42 proteins. We 
detected a slight increase in srGAP1–Cdc42 protein com-
plex in CE48T cells stably expressing SLIT2 than in control 
cells (Fig. 4B). In addition, SLIT2 knockdown decreased the 
srGAP1–Cdc42 complex formation in CE81T cells (Fig. 4C), 
suggesting that the loss of SLIT2 can increase cell migration 
and decrease srGAP1–Cdc42 signal transduction.
Translocation of p-FAK and p-Paxillin 
Is Involved in SLIT2-Mediated 
Migration Suppression
It has been shown that various small GTPase proteins, 
such as Cdc42, facilitate changes in FAK activity and local-
ization to alter the polymerization or stabilization of actin and 
microtubule filaments.15–17 Therefore, we examined whether 
loss of SLIT2 causes Cdc42-dependent translocation of pro-
teins in focal adhesion complex such as p-FAK and p-Pax-
illin to peripheral actin cytoskeleton. First, we performed 
Western blot assay for p-FAK, FAK, p-Paxillin, and Paxillin 
in cells overexpressing or with knocked down SLIT2. The 
results showed no change in the overall cellular protein levels 
(Supplemental Digital Content 7, http://links.lww.com/JTO/
A721). Therefore, we analyzed the localization of p-FAK and 
p-Paxillin by immunocytochemical staining. The location of 
p-FAK and p-Paxillin in CE48T stably expressing SLIT2 and 
SLIT2 knockdown CE81T cells was detected using a fluo-
rescent microscope. Decreased of membrane p-FAK (green) 
and p-Paxillin (red) staining were observed in CE48T stably 
TABLE 1.  Univariate and Multivariate Cox Regression Analyses of Risk Factors for Cancer-Related Death in ESCC Patients
Characteristicsa
Univariate Analysis Multivariate Analysis
HR (95% CI) pa HR (95% CI) pa
SLIT2 protein 0.001 0.036
  Preserved 1.00 1.00
  Absent/decreased 1. 88 (1.31–2.70) 1. 55 (1.03–2.35)
Gender 0.136 0.697
  Female 1.00 1.00
  Male 1.87 (0.82–4.23) 1.19 (0.50–2.80)
Tumor stage 0.005 0.198
  Early (I + II) 1.00 1.00
  Late (III + IV) 1.67 (1.17–2.39) 1.44 (0.83–2.52)
Primary tumor invaded status (T) 0.004 0.009
  T1 1.00 1.00
  T2 3.04 (1.28–6.71) 2.66 (1.08–6.52)
  T3 3.39 (1.75–6.56) 3.92 (1.74–8.83)
  T4 3.58 (1.63–7.86) 2.86 (1.03–7.95)
Lymph node metastases (N) 0.038 0.797
  No 1.00 1.00
  Yes 1.49 (1.02–2.16) 1.08 (0.62–1.88)
Local advanced 0.207 0.172
  No 1.00 1.00
  Yes 1.31 (0.86–2.00) 0.65 (0.35–1.20)
aBold values indicate statistical significance (p < 0.05).
CI, confidence interval; HR, hazard ratio; ESCC, esophageal squamous cell carcinoma.
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overexpressing SLIT2 compared with the control cells (Fig. 
4D). In contrast, an increase of membrane p-Paxillin and 
p-FAK staining was observed in SLIT2 knockdown CE81T 
cells compared with the control cells (Fig. 4E). Cell mem-
branes where the SLIT2 function is compromised, showed 
increase in cell branching and decrease in retraction, result-
ing in an increase in arborization (arrows in Fig. 4D and E). 
These data suggested that SLIT2 affects cell motility, in part, 
through the regulation of p-FAK and p-Paxillin to localize on 
ESCC cell membrane.
Loss of SLIT2 Accelerates ESCC Lung 
Metastasis in Animal Model
According to the above results, we speculated that 
SLIT2 expression inhibited the migration of tumor cells and 
loss of SLIT2 could facilitate tumor cells metastasis. To inves-
tigate the effect of si-SLIT2 on tumor metastasis in vivo, we 
performed experimental metastasis assay, a classic murine 
model to study metastasis where cancer cells injected into the 
tail vein are allowed to circulate and highly metastatic can-
cer cells would typically give rise to lung metastases.18 SLIT2 
knockdown CE81T cells or control cells were intravenously 
injected into SCID mice via the tail-vein. Mice were killed 
after 18 weeks and lung tissues were collected. As shown in 
Figure 5A, the group of mice injected with SLIT2 knockdown 
CE81T showed more tumor nodules in lung tissue than the 
control group. Lung tissues were sectioned for hematoxylin 
and eosin staining examination and there were significantly 
more tumor nodules in SLIT2 knockdown group than the con-
trol group (Fig. 5B and C). The Western blots showed SLIT2 
expression in CE81T cells before the injection (Fig. 5D).
To examine the protein expression level of p-FAK and 
p-Paxillin in vivo, we performed tissue-immunohistochem-
istry on lung tissues of mice that were injected with SLIT2 
knockdown CE81T cells or control cells. The data showed 
an increased p-FAK and p-Paxillin membrane expression 
in tumor xenograft from SLIT2 knockdown CE81T group 
as compared with the control group (Fig. 5D and E). Taken 
FIGURE 2.  Low SLIT2 expression is associated with SLIT2 promoter hypermethylation in ESCC patients and cell lines. A, The 
promoter methylation analyses (upper panel) and mRNA (lower panel) of SLIT2 genes in four representative ESCC patients. The 
primer sets used for amplification are designated “U” for unmethylated or “M” for methylated genes. HET-1A is an unmethyl-
ated control, and SssI-treated HET-1A is a methylated control. B, An inverse correlation between DNA methylation and mRNA 
expression was found in tumor from 50 ESCC patients (p = 0.049 by linear regression analysis). C, A positive correlation 
between protein and mRNA expression and a negative correlation between protein expression and SLIT2 DNA methylation 
were found in tumor from ESCC patients (p = 0.024 and p = 0.040, by χ2 analysis). “+” indicates mRNA or protein normal 
expression or promoter hypermethylation as opposed to “−”, which is low expression or no promoter hypermethylation of the 
corresponding sample. The percentage of concordant group (white bar) and discordant group (gray bar) are indicated at the 
top. D, Methylation level of SLIT2 was significant lower in demethylation reagent (Aza) treated than DMSO treated ESCC CE48T 
and CE81T cell lines. E, mRNA expression level of SLIT2 was higher in Aza treated than DMSO treated cell lines. P values were 
calculated by two-tailed paired t test. Data represent mean ± SD (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001. ESCC, esophageal 
squamous cell carcinoma.
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together, these results indicated that SLIT2 expression neg-
atively correlates with membrane expression of p-FAK and 
p-Paxillin and tumor metastasis in vivo.
DISCUSSION
In the present study, we provide new evidence that 
SLIT2 is a suppressor of ESCC progression. The SLIT2 is 
important in controlling ESCC cell migration mediated by 
srGAP–Cdc42 pathway. Silencing of SLIT2 induces Cdc42 
activity and promotes p-FAK and p-Paxillin localization to 
ESCC cell membrane. In addition, low expression of SLIT2 
protein correlated with late stage disease and poor OS and 
DFS, suggesting SLIT2 can serve as a prognostic biomarker 
of ESCC metastasis.
Our clinical data shows for the first time that low 
expression of SLIT2 correlates with primary tumor invaded 
status and predicted postoperative cancer recurrence in ESCC 
patients (Table 1 and Fig. 1). Thus, the expression of SLIT2 
may be a useful molecular marker for poor prognosis of 
ESCC patients. In tumor etiology of progression and metasta-
sis, the tumor microenvironment of the local host tissue may 
represent an active participant in tumor-host interaction.19 
Interestingly, Chang et al. found that low SLIT2 expression 
in the stromal fibroblasts correlates with lymph node metas-
tasis in breast cancer.20 Therefore, we speculated that the use 
patients’ plasma as a prognostic tool in ESCC may be worthy 
of further investigation.
In our cellular studies, cell motility was reduced when 
SLIT2 was stably overexpressed, but SLIT2 knockdown 
increased cell motility in ESCC cell model (Fig. 3). Consistent 
with our data, low expression of SLIT2 increased cell migra-
tion in lung cancer and invasive cervical cancer.13,21 In addi-
tion, SLIT2 expression inhibits invasion of glioma cells and 
migration of breast cancer cells.10,22 SLIT2-transfected 
HT1080 fibrosarcoma cells forms significantly fewer pul-
monary metastatic nodules than the parental and control 
vector-transfected cells.23 These results supported our data 
that SLIT2 is a suppressor of cell migration. Notably, Kim et 
al. showed that SLIT2 inhibited cell proliferation and tumor 
growth in cell and xenograft models using A431 epidermoid 
squamous carcinoma cell line.23 However, our results showed 
that SLIT2 knockdown CE81T and SLIT2 overexpression 
CE48T did not alter the cell proliferation and foci formation 
(Supplemental Digital Content 5, http://links.lww.com/JTO/
A719). The context-dependent role of SLIT2 to serve as an 
anti-growth or anti-metastasis tumor suppressor may be due 
in part to the interaction with different effectors in various 
tumors. Importantly, our results demonstrated that the group 
of mice injected with SLIT2 knockdown CE81T showed more 
tumor nodules in lung tissue than the control group (Fig. 5). 
The presence of residual CE81T cells competent to maintain 
low SLIT2 expression suggests that si-SLIT2 cells were capa-
ble of extravasation, colonization, and growth in vivo. A simi-
lar persistent expression after siRNA knockdown in vivo had 
FIGURE 3.  SLIT2 negatively regulates cell migration ability in CE48T and CE81T ESCC cells. A, Migration ability decreased 
dramatically in CE48T stably overexpressing SLIT2 assessed by wound healing assay. B, SLIT2 knockdown (si-SLIT2) promoted 
cell motility in CE81T cells. C, Migration was inhibited in CE48T cells and CE81T cells after addition of CM from CE48T stably 
overexpressing SLIT2 cells (CM-SLIT2) than CE48T cells without ectopic SLIT2 expression (CM-Con). SLIT2 concentration in 
the medium was measured by Western blot and is indicated at the top. β-actin was used to quantify the total cellular protein in 
cells from which the CM were derived. P values were calculated by two-tailed paired t test. Data represent mean ± SD (n = 3) 
(Original magnification: 100×). CM, conditioned media.
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been observed in other studies.24,25 It is worth investigating 
whether there is a paracrine loop between metastatic tumor 
nodules and the surrounding stromal upon SLIT2 knockdown. 
Our clinical, cellular, and animal data suggested that SLIT2 is 
a suppressor of cell migration and tumor metastasis in ESCC.
Cdc42 is a small GTPase and Cdc42 GTP-bound form, 
the active form of Cdc42, promotes actin polymerization and 
regulates the extension and branching of actin filament and 
cell protrusion.12,26 Recently, Myers et al.27 found that SLIT2 
application rapidly reduced protrusion and Cdc42 activity at 
the growth cone periphery and regulation of FAK activity cor-
responded closely with Cdc42 in response to SLIT2, indicating 
that SLIT2 inhibits lamellipodial protrusion and axon out-
growth via inactivation of FAK in neuronal cells. In addition, 
Bongiorno-Borbone et al.17 showed that a specific pool of FAK 
in nerve cells was translocated from the cytosol to the plasma 
membrane in order to allow FAK-mediated transduction of 
extracellular signals. In addition, FAK was regulated by both 
phosphorylation and actin assembly. Interestingly, our data 
revealed that knockdown of SLIT2 facilitated the translocation 
of p-FAK and p-Paxillin to peripheral actin cytoskeleton (Figs. 
4E and 5E). On the other hand, SLIT2 overexpression decreased 
Cdc42 activity in ESCC cells (Fig. 4A and B). According to 
these results, Cdc42, p-FAK, and p-Paxillin may be involved 
FIGURE 4.  Cdc42-related signaling pathways involve in SLIT2-mediated migration suppression in ESCC. A, Overexpression of 
SLIT2 down-regulated the Cdc42 activity manifested by decreasing the level of GTP-Cdc42 (left); knockdown of SLIT2 up-regulated 
Cdc42 activity (right). IP assay using the anti-srGAP1 antibody showed (B) an increased interaction of srGAP1 with Cdc42 in CE48T 
stably overexpressing SLIT2 and (C) a decreased interaction of srGAP1 with Cdc42 in SLIT2 knockdown CE81T cells. An immunoblot 
of long exposure for Cdc42 input is shown to justify the interaction of srGAP1 with Cdc42 observed. The immunofluorescence assay 
illustrated (D) a decrease of membrane localization of p-Paxillin and p-FAK staining in CE48T stably overexpressing SLIT2 compared 
with control cells and (E) an increase of membrane p-Paxillin and p-FAK staining in SLIT2 knockdown CE81T compared with control 
cells. 4',6-diamidino-2-phenylindole stains show the nuclear immunoreactivity. A 3× enlarged image is shown in the right panel of 
each group, and its original region is indicated by the dotted line in the left panel. Representative blots and images were selected 
from at least three independent experiments. ESCC, esophageal squamous cell carcinoma; IP, Immunoprecipitation.
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in SLIT2-mediated suppression of migration in the peripheral 
lamellipodia of motile ESCC cells. Of note, previous reports 
showed that AKT/GSK3β/β-catenin pathway were involved 
in SLIT2-mediated cell motility control in other cancers.13,28,29 
Therefore, we further detected the p-AKT expression in CE48T 
and CE81T cells with ectopically expressed SLIT2. Our data 
showed no difference in p-AKT expression between control 
cells and SLIT2 overexpression cells (Supplemental Digital 
Content 8, http://links.lww.com/JTO/A722). The results sug-
gested that AKT pathway may not involve in SLIT2-mediated 
cell motility in ESCC cell model that we tested.
In conclusion, our clinical, cellular, and animal results 
provide the compelling evidence that SLIT2 is a migration 
suppressor and a potential prognostic biomarker for ESCC via 
inhibition of srGAP–Cdc42 signaling and membrane localiza-
tion of p-FAK and p-Paxillin in ESCC. Our findings provide 
a plausible mechanism of SLIT2-mediated cell migration and 
tumor metastasis of ESCC.
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